Strategic partnerships Potential sales opportunity with Bio-Rad Laboratories due to the existing announced partnership, suggesting a receptive market for Globavir’s infectious disease diagnostics and therapeutics collaboration capabilities.

Dengue focus Primary sales angle centers on dengue therapeutics and diagnostics leveraging the 505(b)2 regulatory pathway, addressing a large global patient pool and enabling accelerated market entry.

Platform leverage Globavir’s integrated platform combining proprietary diagnostics with therapeutic candidates positions it for bundled or integrated solutions for infectious disease programs in clinical and diagnostics spaces.

RNA viral expansion Identified candidate compounds with activity against multiple viruses (West Nile, Japanese Encephalitis, Ebola, Marburg, Hunta) open cross-licensing or co-development discussions with partners targeting emergent viral threats.

Early-stage traction Funding of thirteen million and a lean team (11-50 employees) indicate a nimble, growth-ready organization with room for early customer pilots, pilot programs, and fundraising-backed BD opportunities with strategic partners and CROs.